O.B NATION IL	STAGE WORKSHEET (~O/EO)				
3. APPL. NO. 09/830806	INTERNATIONAL APPL. GB99/0.2518				
PLICATION FILED BY: 20 MOS.,					
TERNATIONAL APPLICATION PAPERS IN THE APPLICATION FILE:					
International application)/				
Article 19 amendments	409 annexes to IPER				
Priority Document(s) No.	PCI/ISA/210 (Search report)				
Request Form PCT/RO/101	Search report References				
PCT/IB/302	Other Papers filed				
PCT/IB/304	HITPO Property				
PCT/IB/306	WIPO PUBLICATION				
PCT/IB/308	PUBLICATION NO. WO 17 35079				
VCT/IB/331	PUBLICATION DATE TO THE PUBLICATION LANG.,				
OTHER PCT/IB/	NOT PUBLISHED				
PCT/IPEA/409 also 416	TT ()				
	U.S. onlyRequested				
EIVED FROM THE APPLICANT: ational application basic fee paid appress Processing Requested ranslation of the International Application sed the IB copy of the IA escription taims reign Language in drawing ticle 19 Amendments nendment used in application ticle 34 Amendment nendment used in application NA 94 transaction done	(other than checked above) Preliminary Amendment(s) filed Second submission Information Disclosure Statement Second submission Assignment Forward to Assignment Branch Substitute Specification Small Entity Statement type Oath/Declaration (date submitted Not executed Power of Attorney Change of Address				
C Receipt of Request (PTO – 139 Acceptable oath/declaration receive Date DATE NOT O 903 Notice of Acceptance O 905 Notice of Missing Require	30 JUL 2001 s met 30 JUL 2001 ICE COMPLETED 8/13/1/				
2917 Notice of A defective oath or declaration					
2916 Notice of defective respon	CA COMMUNICATION				
2913 Notice of defective translation					
) 909 Notification of Abandonment					
THEIR OF THE PROPERTY OF THE P					



Application No. 09/832,269

Applicant(s)

Peyman

Office Action Summary

Examiner
Zohreh Fay

Art Unit **1614**



The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
	for Reply					
	ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE	3	_ MONTH(S) FROM		
	THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the					
mailing date of this communication.						
- If NO p	- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.					
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any						
earned Status	patent term adjustment. See 37 CFR 1.704(b).					
1) 🗌	Responsive to communication(s) filed on			·		
2a) 🗌	This action is FINAL . 2b) 💢 This action	FINAL. 2b) 💢 This action is non-final.				
3) 🗆	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposit	tion of Claims					
4) 💢	Claim(s) <u>1-21</u>			is/are pending in the application.		
4	la) Of the above, claim(s)			is/are withdrawn from consideration.		
5) 🗆	Claim(s)			is/are allowed.		
6) 💢	Claim(s) <u>1-21</u>			is/are rejected.		
7) 🗌	Claim(s)			is/are objected to.		
8) 🗆	Claims	are	subject	to restriction and/or election requirement.		
Application Papers						
9) The specification is objected to by the Examiner.						
10)	10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	The proposed drawing correction filed on	-				
	If approved, corrected drawings are required in reply t					
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) 🗆	a) □ All b) □ Some* c) □ None of:					
1. Certified copies of the priority documents have been received.						
:	2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
*See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachm		🗖 .				
_	tice of References Cited (PTO-892)	_	•	0-413) Paper No(s)		
_	2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 2 6) Other:					
ai XI iuu	ormation Disclosure Statement(s) (P10-1449) Paper No(s)	6) Uther:				

Application/Control Number: 09/832,269

Art Unit:

Claims 1-21 are presented for examination.

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 3-5, 9, 10, 11, 15, 16, 17, 18 and 21 are rejected under 35 U.S.C. 102 (b) as being anticipated by Peyman et al.. Peyman et al. Teach the use of semiconductor microphotodiode which is surgically inserted in subretinal space for the treatment of retinitis pigmentosa and restoring the vision. The above reference also teach that such implant needed external connections for power.

Claims 12, 19 and 20 are rejected under 35 U.S.C. 102 (b) as being anticipated by Majji et al. Teach the use of an electrode array being surgically inserted in the epiretinal side for stimulation of vision due to photoreceptor loss.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

Application/Control Number: 09/832,269

Page 3

Art Unit:

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act

of 1999 (AIPA) do not apply to the examination of this application as the application being

examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35

U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the

amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 2, 7, 8 and 13 are rejected under 35 U.S.C. 102 (e) as being anticipated by Wen

et al. (U.S. Patent 6,066,675). Wen et al. Teach the use of an alpha adrenergic agonist or a beta-

adrenergic agonist for the stimulation of growth factor expression and the treatment of retinal

diseases. See column 3, lines 48-67. The subretinal (interphotoreceptor) application is taught by

the above reference. See column 4, line 5. Slow release encapsulated is also used by the above

reference. See column 4, lines 26-38.

2. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Examiner Fay whose telephone number is (703) 308-4604.

ZOHREH FAY PRIMARY EXAMINER GROUP 1200

zohet Fr